Background: Individualized diabetes management would benefit from prospectively identifying well-controlled patients at risk of losing glycemic control.
C linical guidelines recommend intensifying glucose-lowering therapy to achieve hemoglobin A 1c (HbA 1c ) <7.0% for most adults with type 2 diabetes. [1] [2] [3] Patients at highest risk for uncontrolled disease benefit from close monitoring and early intervention. Such efforts usually focus on patients with known risk factors for poor glycemic control: those with currently or recently uncontrolled disease, insulin-treated, younger, or with socioeconomic barriers to care. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, patients with controlled diabetes and without obvious risk factors may also experience glycemic deterioration and benefit from early identification and preemptive management to optimize long-term control. 17, 18 Historically, such efforts were hindered by difficulty recognizing high-risk individuals, particularly as an individual patient's risk profile may differ from population-level estimates.
The development of advanced analytic methods and growing availability of electronic health-related data paved the way to address methodologic barriers to risk stratification. In particular, machine learning approaches based on datadriven learning algorithms can extract information from complex raw data rather than predefined a priori assumptions, but these methods are traditionally used for cross-sectional data, limiting their application to longitudinal clinical problems. In this study, we build on these methods to construct a novel machine learning framework for complex longitudinal data analysis, which would be useful in a wide range of clinical applications. Specifically, we use a Bayesian estimation of the generalized linear mixed model (GLMM), with the random effect component replaced by a mixture of normal distributions. 19 This procedure enables data-driven discovery of homogenous longitudinal trajectories characterized by time-dependent covariates. We then apply the model to identify trajectories of HbA 1c change among adults with stable controlled type 2 diabetes and predict who will lose glycemic control. To determine which patient characteristics are most predictive of glycemic trajectories, we use a novel random forest feature contribution (rfFC) method, 20 which allows for the identification of important features at both the population and individual patient levels. Such information can be leveraged to characterize patient and disease phenotypes, study longitudinal risk factors and outcomes, and facilitate individualized patient-centered diabetes care.
METHODS

Study Population
The study cohort consisted of 27,005 adults, age 18 years and older, with stable and controlled type 2 diabetes included in OptumLabs Data Warehouse (OLDW), a large administrative claims database of commercially insured and Medicare Advantage beneficiaries across the United States. 21, 22 Diabetes was defined by Healthcare Effectiveness Data and Information Set criteria 23 ascertained using medical and pharmacy claims from 12 months preceding the index HbA 1c . Stability of glycemic control before cohort entry was ensured by (1) index HbA 1c <7.0% between January 1, 2001 and December 31, 2011; and (2) preindex HbA 1c <7.0% immediately preceding the index HbA 1c and no earlier than 24 months. To focus on patients at lowest presumed risk of glycemic deterioration, we excluded people using insulin within 120 days before the index date; or with history of diabetic ketoacidosis (ICD-9-CM 250.1x), hyperglycemic hyperosmolar state (ICD-9-CM 250.2x), diabetic coma (ICD-9-CM 250.3x), severe hypoglycemia (ICD-9-CM 251.x, 250.8x 24 All study data were accessed after deidentification consistent with Health Insurance Portability and Accountability Act expert deidentification determination. Because this study involved analysis of preexisting, deidentified data, it was exempt from Institutional Review Board approval. 25 
Independent Variables
Variables used in the analysis were selected based on what is commonly available in the electronic health records, obtained as part of routine care, and not contingent on a concomitant face-to-face clinical encounter. This includes patient age (at the time of the index HbA 1c ); sex; race/ethnicity; Charlson/Deyo comorbidities 26 documented within 12 months of the index date; geographic region; medications filled 120 days before to 24 months after the index date (but only medications before and at the time of the index HbA 1c were used in the models); and the index, preindex, and all other HbA 1c values during 24 mo of follow-up). HbA 1c results were identified using LOINC codes 4548-4, 4549-2, 17856-6, 59261-8, 62388-4 and 4547-6. Diabetes medications were grouped into 9 classes (see Table, Supplemental Digital Content 2, http://links.lww.com/MLR/B471, which categorizes and lists diabetes medications).
We included a measure of HbA 1c testing frequency during 24 months of follow-up, categorized as ≤ 2, 3-4, or ≥ 5 tests per year, as short-term testing and monitoring plans are determined a priori and may influence glycemic control. 27 Medication changes at the time of the index HbA 1c were recorded, classified as no change, class change, intensification (addition of ≥ 1 drug or insulin start), or deintensification (removal of ≥ 1 drug). Treatment change during follow-up was not ascertained, as this data would not be available at the pointof-care when trajectory class assignment would be made.
Statistical Analysis Data Exploration
Basic exploration of longitudinal HbA 1c profiles of each patient suggested that the evolution of each profile can be modeled by a linear function over time where the parameters of the function may differ across patients. We therefore selected the GLMM with random intercept and slope on the time variable.
Bayesian Mixture of Generalized Linear Mixed Effects Model (MGLMM)
Because effect of patient characteristics on HbA 1c may vary across time and patients, we used a Bayesian approximation of the mixture extension of the GLMM where the random effect component is assumed to follow a mixture of normal distributions. 19 The MGLMM specifies that there is unobserved clustering of random effect parameters across an unknown number of population subgroups (trajectories) with different weights. Model parameters of MGLMM were estimated using the Markov Chain Monte Carlo (MCMC) method and implemented using the R package mixAK, 19 which has the advantage that if the computation fails (ie, does not converge), then model assumptions are violated 28 indicating that the proposed model is not appropriate for the data and should be rejected. We assumed weakly informative priors for all fixed effects parameters, set the mixture means to 0, and assumed equal probability for the mixture weights (ie, equal a priori probability of assignments of patients to trajectories). We assessed convergence of the posterior distribution of the parameters of MGLMM in the MCMC simulation through traceplots and autocorrelation plots, and all indicated proper convergence.
Data-driven Model Validation and Selection of the Optimal Number of HbA 1c Trajectories
We assessed robustness and stability of the models and selected the optimal number of trajectories through 2 "internal" and 1 "external" validation techniques. 29 The internal validation methods are based on information used to generate the models without reference to external information, while the external method uses the derived trajectories. We used the external method to assess the quality of the trajectory classification and not the fit of the MGLMM model, a procedure that is best assessed by the internal methods and the convergence of the MCMC.
The penalized expected deviance (PED) and posterior distribution of deviances were used as internal validation statistics. The PED 30 is the most commonly used Bayesian measure to assess model fit, where lower values indicate better model. However, model selection based on a single criterion such as the PED ignores uncertainty in the comparison, which increases with increasing number of model parameters. 19, 31 An alternative approach is to assess the full posterior distribution of the deviances of the models. Thus, suppose Diff is the difference in deviance between a large and a small model, if the posterior probability P(Diff < −2log(9) = −4.39) is ≥ 0.9, then there is strong evidence in favor of the larger model. 31 We computed these statistics by fitting 5 MGLMM models with the number of mixture components set to k = 1, … ,5.
For external validation, we used the rfFC method to predict a patient's trajectory based on new data and assessed how each variable contributes toward this classification. The assumption is that similar patients at baseline will follow the same trajectory, and if trajectory assignments by the MGLMM model are accurate, this will be reflected by high accuracy of the prediction model. Random forest 32 is a machine learning method that constructs multiple decision trees on a bootstrap sample of the training data and then combines the predictions by averaging or majority voting. This produces a ranking score for each variable in the model to reflect its importance to the prediction task. This ranking score can help in model interpretation or dimension reduction; however, it is a population average score that is not useful for assessing the importance of individual patient characteristics. A variable may be an important risk factor for the population, but not affect a specific individual or subgroup.
The rfFC 20 is a recent extension of the random forest variable importance [or feature contribution (FC)] for each individual in the training data, with the additional benefit that the FC can also be predicted for new data. This allows to further assess the accuracy of the rfFC model and MGLMM trajectory classifications for each patient, as a good match between the average FCs of the training and test sets reflects a high quality model. 20 FC = 0 indicates that the variable is irrelevant with respect to assigning a patient to a given trajectory, positive values indicate that the variable is influential toward classification to the reference trajectory (in our study, T3), and negative values indicate that the variable is influential toward classification to the other trajectories. We used data at index HbA 1c for training and data for 0-3 subsequent months for testing. For each medication, we created an indicator variable to indicate if that medication was filled at least once in the 0-3 months. A 5-fold cross-validation training procedure was implemented and the best model in terms of accuracy was used for prediction on the test set.
We also used the rfFC method to quantify FCs for one randomly selected patient from each trajectory. These patientlevel FCs were qualitatively compared with the median (or population-level) FCs obtained for the whole study sample.
To characterize the trajectory differences in patient baseline characteristics, we used the Pearson χ 2 test for categorical variables and the Kruskal-Wallis H test for continuous variables. All statistical tests were performed at 5% level of significance.
RESULTS
The study cohort included 27,005 adults with type 2 diabetes and mean index HbA 1c 6.22%. Included patients were, on average, 58.4 years old, 51.1% were male, and 57.6% were white (Table 1) . At baseline, 34.4% of patients were treated with lifestyle therapy; 37.6%, with 1 glucoselowering medication; 21.4%, with 2 drugs; and 6.6%, with ≥ 3 drugs. The majority of patients were from South United States (55.7%), with the remainder from the Northeast (25.6%), Midwest (11.0%), and West (7.7%).
Trajectories of Glycemic Change
Implementation of the Bayesian MGLMM with k = 1, 2, 3, 4, 5 possible mixture components supported a 3 trajectory model (Fig. 1 ) based on its low PED, lowest median difference in FCs between the training and test datasets, and principles of parsimony and interpretability. Models with k = 1 and k = 2 trajectories had much higher PED than models with k = 3, 4, 5 trajectories (Table A1) . Models with k = 4 and k = 5 trajectories were redundant, with P(Diff < −4.39) = 0.9 and highest posterior density interval of the mean difference in the deviance spanning 0 (Table A2) .
With respect to the rfFC model, models with k = 4 and k = 5 resulted in lager mismatch in FCs between the training and test datasets compared with the k = 3 model ( In addition, the accuracy and positive predictive values for the best k = 3, 4, 5 rfFC models selected through cross-validation were: 0.88, 0.82, 0.87 and 0.54, 0.41, 0.45, respectively, thus indicating the superiority of the k = 3 model. It should be noted that the rfFC method was used in this study as a validation and interpretation tool, and not for predicting trajectories; predictions are handled by the MGLMM model. As such, these performance measures should be interpreted in terms of selecting the optimal number of trajectories and not for predicting trajectories for new patients.
The first trajectory (T1), comprised of 302 (1.1%) patients, was notable for rapid deterioration of glycemic control with mean HbA 1c rising from 6.05% to 8.75% in 24 months. T2 included 903 (3.4%) patients who demonstrated slower deterioration of glycemic control with mean HbA 1c rising from 6.53% to 8.40%. T3 was the most common and included 25,800 patients (95.5%) who maintained glycemic control, with mean HbA 1c changing slightly from 6.21% to 6.56%.
Patient Phenotypes
Patients following the 3 trajectories differed significantly in age, sex, and index HbA 1c (P < 0.001 for all) ( Table 1 ). T1 patients were younger (55.2 y), more likely to be male (62.6%), and had lower mean index HbA 1c (6.05%) compared with patients in the other 2 trajectories. In contrast, T3 patients were older (58.5 y), less likely to be male (50.7%), and had mean index HbA 1c 6.21%. They were similar in their racial, geographic, and comorbidity profiles.
Baseline medication use differed among patients in the three trajectories. Patients in T1 and T2 were treated with monotherapy (33.8% and 31.6%, respectively), 2 drugs (27.5% and 30.8%, respectively), or ≥ 3 drugs (13.6% and 13.4%, respectively). Patients in T3 were most likely to be controlled with one (37.9%) or no (34.9%) glucose-lowering medications. Metformin was the most common class of medications in all three trajectories, used by 55.3% of patients in T1, 59.1% of patients in T2, and 48.4% of patients in T3. Sulfonylureas were used most often by patients in T1 (42.1%), while DPP-4 inhibitors and GLP-1 receptor agonists were most commonly used by patients in T2 (12.0% and 3.0%, respectively). Figure 2 presents the population-level FCs in classifying patients into the 3 trajectories, with T3 as the referent 
Diabetes Management in Each Trajectory
Treatment regimens were variably intensified among patients in all 3 trajectories (Fig. 3 and see Table, Supplemental Digital Content 4, http://links.lww.com/MLR/B473, which presents the number of medications used over time among patients in the 3 glycemic trajectories). The fraction of patients taking no glucoselowering medications was constant in T3 (around 30%), decreased steadily in T2 (24.3%-16.7%), and decreased but then rose again in T1 (25.2% at index date, 14.5% at 15-18 mo, 25.7% at the end). The fraction of patients treated with one-medication regimens decreased steadily in T1 (33.8%-24.6%) and T2 (31.6%-25.3%) as patients were intensified to ≥ 2 medications, but remained stable in T3 (around 38%). Two-medication regimens increased and then decreased in T1 (27.5% at index date, 35.0% at 15-18 mo, 27.3% at the end), but increased steadily in T2 (21.0%-35.8%). Use of ≥ 3 medications increased in all trajectories: 13.6%-22.5% in T1; 13.4%-22.3% in T2; and 6.3%-7.8% in T3. 
DISCUSSION
Patient-centered diabetes care is predicated on proactively identifying patients at risk for deterioration of glycemic control. While current HbA 1c is an important predictor of future glycemic control, patients with controlled disease may still experience rise in HbA 1c requiring clinical attention. In this study, we developed a machine learning framework to identify 3 distinct trajectories of glycemic change among 27,005 presumably low risk adults with stable controlled type 2 diabetes, 5% of whom experienced marked deterioration of glycemic control with HbA 1c approaching 9% within 2 years. This algorithm has the potential to be used across a wide spectrum of settings and practices as it is based on variables obtained during routine care, available in electronic health records, and not predicated on a concurrent face-to-face encounter.
As expected, the vast majority (95%) of patients maintained glycemic control, with mean HbA 1c increasingly negligibly from 6.21% to 6.56% over 2 years. These patients were more often older, female, and treated with lifestyle therapy at cohort entry. However, a small but clinically important subset of patients experienced marked deterioration of glycemic control. HbA 1c rapidly rose from 6.05% to 8.75% in 1.1% of patients who were younger, more likely to be male, and more likely to be treated with multiple glucose-lowering drugs at cohort entry. While the majority of these patients were ultimately taking ≥ 2 drugs (this variable was not included in the predictive model as these treatment changes occurred after cohort entry), there was a late rise in the percent of patients taking fewer or no medications despite HbA 1c exceeding 8%, suggesting potential nonadherence to therapy. In another 3.3% of patients (T2), HbA 1c rose gradually from 6.53%-8.40%. These patients were less likely than patients in T1 to take ≥ 3 diabetes medications despite elevated HbA 1c , and were least likely to have their treatment intensified at the time of index HbA 1c , potentially reflecting inadequate treatment intensification and/or nonadherence to glucose-lowering polypharmacy. The frequency of HbA 1c testing also differed among the groups. Stably controlled patients in T3 were most likely to be tested twice annually, as recommended by most clinical guidelines, 1-3 although nearly two-thirds were tested quarterly or more often. Patients losing glycemic control were monitored more frequently, as recommended by the guidelines, 1-3 but nearly 7% of rapidly deteriorating patients in T1 still had their HbA 1c checked once or twice per year. Time to reassessment is determined a priori (eg, during the index clinical encounter) based on the anticipated likelihood of clinical change based on information available at the time. The lack of close monitoring of patients in T1 and T2, which may be due to patient-factor, providerfactor, or system-factor, may have contributed to their poor glycemic outcomes.
Our study confirmed several previously observed characteristics associated with loss of glycemic control, including younger age, male sex, and need for multiple glucose-lower medications. [5] [6] [7] [8] Such patients may benefit from educational and clinical resources to help manage their diabetes irrespective of their HbA 1c , including multidisciplinary programs targeted at medication adherence, education, and self-management. 4 Administrative data does not allow for ascertainment of the reasons why glycemic control deteriorated, such as failure of treatment intensification, nonadherence, adverse effects or contraindications to intensive therapy, lack of access to health care, or competing demands. Importantly, none of the patients in the study had documented severe hypoglycemia (per study exclusion criteria), and there was no difference in comorbidity burden among patients in the 3 trajectories, so it is unlikely that different treatment goals or contraindications to intensive therapy explain the entirety of differences in glycemic control and treatment. Furthermore, all patients had commercial insurance and thus access to health care, although different benefit designs may have placed some patients at greater financial burden than others. Our study dataset and models were further limited by absence of psychosocial information, which has been shown to be important in identifying glycemic trajectories in type 1 diabetes, [9] [10] [11] [12] and may similarly contribute to glycemic patterns among adults with type 2 diabetes. Administrative data also does not capture lifestyle habits and weight changes, which can contribute to glycemic change. Race/ethnicity did not contribute significantly to trajectory assignment, such that commonly observed disparities in glycemic control 8 may reflect other important risk factors such as access to health care and medications. [13] [14] [15] Our study was conducted among commercially insured and Medicare Advantage beneficiaries, so the results may not fully generalize to uninsured or publicly insured patients or to situations where social determinants of health preclude adequate access to health care. 16 Nonetheless, the objective of this study was to develop a modeling approach that would be robust even with limited data, and therefore focused on variables routinely collected and electronically catalog in clinical practice. Prior studies of longitudinal glycemic control have focused almost exclusively on children and adolescents with type 1 diabetes. [9] [10] [11] [12] 33 One study was conducted among adults with type 2 diabetes, but did not focus on controlled patients. 34 By applying a novel analytic framework to administrative and laboratory data from a large and diverse national cohort of adults with type 2 diabetes, our study allowed for data-driven identification of HbA 1c trajectories and discovery of potentially meaningful patient-level and population-level risk factors that warrant further evaluation. Furthermore, the innovative analytic approach used in this study distinguished between population-level FCs, representing population-level risk factors, and individual FCs specific to the unique patient. Classical statistical analyses cannot simultaneously provide population and individual risk assessment, yet both are needed for clinical practice. In the current era of proactive population health management and individualized medicine, such analyses can leverage electronic data sources for improved patient care and experience. Evaluation of this approach in clinical practice is needed and is planned for the future. Higher absolute mean difference in deviances indicates greater divergence between the compared models. The HPD is a Bayesian credible interval that is analogous to confidence intervals used in classical statistics. In this analysis, which evaluates for differences between 2 models, HPD intervals that span 0 are not significantly different from each other.
HPD indicates highest posterior density. 
